See more : Sodexo S.A. (SW.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Edoc Acquisition Corp. (ADOC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Edoc Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- SIGNA Sports United N.V. (SSU) Income Statement Analysis – Financial Results
- Safilo Group S.p.A. (SFL.MI) Income Statement Analysis – Financial Results
- Trans-Lux Corporation (TNLX) Income Statement Analysis – Financial Results
- Pzena Investment Management, Inc. (PZN) Income Statement Analysis – Financial Results
- SRA Holdings, Inc. (3817.T) Income Statement Analysis – Financial Results
Edoc Acquisition Corp. (ADOC)
About Edoc Acquisition Corp.
Edoc Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the health care and health care provider space in North America and the Asia-Pacific. The company was incorporated in 2020 and is based in Victor, New York.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.54M | 1.80M | 0.00 |
| Gross Profit | -2.54M | -1.80M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 1.80M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 2.54M | 1.80M | 89.34K |
| Other Expenses | 2.54M | -70.30K | -565.30K |
| Operating Expenses | 2.54M | 1.80M | -565.30K |
| Cost & Expenses | 2.54M | 1.80M | -565.30K |
| Interest Income | 314.16K | 20.87K | 8.68K |
| Interest Expense | 36.10K | 5.03K | 0.00 |
| Depreciation & Amortization | 2.54K | 1.80K | 268.02 |
| EBITDA | -5.14K | 898.22 | -1.43K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.54K | -1.80K | -268.02 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.14M | 898.22K | -1.43K |
| Income Before Tax | -7.69K | -899.88 | -1.70K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.14K | 898.22 | -1.43K |
| Net Income | -7.69K | -899.88 | -1.70K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 5.93M | 11.80M | 11.80M |
| Weighted Avg Shares Out (Dil) | 5.93M | 11.80M | 11.80M |
YesCare has Joined Leading Multiagency Initiative on Opioid Use
MONTGOMERY, Ala.--(BUSINESS WIRE)--YesCare, pioneer and foremost provider of correctional healthcare in the United States as a company built on more than 40 years of innovation and earned expertise in the industry, has in partnership with the Alabama Department of Corrections...
Edoc Acquisition Corp. Announces Postponement of Special Meeting of Shareholders on Proposed Business Combination
Victor, NY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (Nasdaq: ADOC) (“EDOC”) announced today that it has postponed its extraordinary general meeting of its shareholders (the “Meeting”) to approve its proposed initial business combination, which was re-scheduled from...
Edoc Acquisition Corp. Announces Postponement of Special Meeting of Stockholders on Proposed Business Combination
Victor, NY, Feb. 23, 2024 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (Nasdaq: ADOC) (“EDOC”) announced today that it has postponed its extraordinary general meeting of its shareholders (the “Meeting”) to approve its proposed initial business combination, which was scheduled for...
Australian Oilseeds and EDOC Acquisition Corp. Announce Effectiveness of Registration Statement and Date of Shareholder Meeting to Approve Proposed Business Combination
~ Shareholder Meeting of EDOC Acquisition Corp. to Approve Business Combination Scheduled for February 26, 2024 ~
Edoc Acquisition Corp. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Victor, NY, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp. (NASDAQ: ADOC) (the “Company”) announced that it received a letter from The Nasdaq Capital Market (“Nasdaq”) on November 30, 2023 indicating that (i) the Company's failure to file its Quarterly...
Arena Investors, Australian Oilseeds Holdings Limited and EDOC Acquisition Corp. Announce an Investment of up to $7 Million and Plans for a $50 Million ELOC
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Arena Investors, LP ("Arena"), a $3.5 billion institutional asset manager, has entered into an agreement with Australian Oilseeds Holdings Limited (“Australian Oilseeds” or “Pubco”), which is a holding company whose subsidiaries following the Business...
Number of Shares and Voting Rights of ADOCIA as of April 30th, 2023
LYON, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter ADOCIA SA (Paris:ADOC), a...
ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 avril 2023
LYON, France--(BUSINESS WIRE)--Regulatory News: 18h CEST – Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers (« AMF »). ADOCIA SA (Paris:ADOC), 115, avenue Lacassagne, 69003...
ADOCIA Announces the Appointment of Olivier Soula as Chief Executive Officer
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the appointment of Olivier Soula...
ADOCIA annonce la nomination d’Olivier Soula au poste de Directeur Général
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et d’autres maladies métaboliques, annonce aujourd’hui la nomination...
Source: https://incomestatements.info
Category: Stock Reports